Sponsor Oversight
Elevating your trials by Seamless Execution, Compliance, and Data Integrity with our Sponsor Oversight mechanism
Elevating your trials by Seamless Execution, Compliance, and Data Integrity with our Sponsor Oversight mechanism
The sponsor holds sole accountability for management and monitoring of clinical trials. Therefore, there should be systems in place to ensure that contracted or outsourced tasks are being closely monitored guaranteeing patient wellbeing and data integrity.
USFDA has recommended the “Guidance for Industry Oversight of Clinical Investigations – — A Risk-Based Approach to Monitoring” emphasizing the importance of effective monitoring to protect human subjects and ensure high-quality studies. Sponsors of clinical investigations involving human drugs are required to provide oversight to ensure the rights, welfare, and safety of subjects and the quality of clinical trial data submitted to the FDA.
As per ICH E6 R2, the sponsor may establish an independent data monitoring committee (IDMC) to assess the progress of a clinical trial, including safety data and critical efficacy endpoints. The IDMC should have written operating procedures and maintain records of meetings. The sponsor should ensure oversight of trial-related duties and functions carried out on its behalf, including those subcontracted to another party by the sponsor’s contracted CRO(s).
Adherence to GCP is crucial and should be prioritized over internal policies and procedures. The contract should address subcontracting and outline the sponsor’s oversight of additional subcontracting. However, key legislative requirements, such as reporting urgent safety measures and serious breaches, are often missing from contracts, potentially leading to non-compliance due to unclear roles and responsibilities.
Zenovel maintains the highest standards for safeguarding patients and ensuring data authenticity through comprehensive supervision procedures, guaranteeing efficient management and monitoring of clinical studies.
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
The international pharmaceutical landscape is inherently connected to the global economy and global trade, which is consisted with the quality and safety assurance , well-controlled quality and safety. Compliance with international pharmaceutical standards has changed from an optional step to a requirement. The Pharmaceutical Inspection Co-operation Scheme (PIC/S Certification) is
We provide affordable, innovative, and high-quality solutions to pharma industry with ethics driven research and increasing accessibility to high quality medicine worldwide
Copyright © 2024 Zenovel. All rights reserved.